SAN FRANCISCO— Collaborative Drug Discovery (CDD) announced that its CDD Vault platform will be implemented by Curve Therapeutics Ltd. (Southampton, UK) to manage its genetically-encoded Microcycle platform and the functional hits and leads generated from it.
Curve is an innovative drug discovery company that has developed a screening platform that directly identifies functional modulators of disease targets in their native cellular environment.
CDD Vault is a ubiquitous, hosted platform used by research teams at pharma, academia, and biotechs to store, mine and manage chemical, biological, and image data from the discovery process. It allows the secure and seamless sharing of data with external partners in real-time thus facilitating true collaborative discoveries.
“It is important that all of our data is easily captured, mined and analyzed and CDD Vault has been straightforward to implement and use. The system will allow us to securely share data with collaborators and investors alike,” said Prof. Ali Tavassoli, Curve’s Founder and Chief Scientific Officer.
“We are delighted to see Curve Therapeutics growing as a company and increasing its pipeline of first-in-class cancer therapeutics. The small molecule leads being generated by Curve give a new hope to finding treatments for challenging diseases,” said Dr. Barry Bunin, CEO of CDD. “We are proud to be able to support Curve Therapeutics in their drug discovery process. Curve has a great combination of technology and human capital that maximizes the potential of success of finding new cures for cancer and other diseases.”
